The Effect Of Botox In Patients With Gummy Smile With And Without Zinc And Phytase Supplementation.
Recruiting now · Not applicable
Conditions studied: Excessive Gingival Display
In brief
Participants with esthetic concern of excessive gingival display who meets the inclusion criteria, will be carried out including history taking, clinical examination and initial therapy. The initial therapy will consist of periodontal treatment (phase I therapy) including supragingival scaling, subgingival debridement if needed. The mechanical plaque control instructions for each patient include brushing and interdental cleaning techniques. Patients who have inadequate crown length and width ratio or short clinical crown will receive esthetic crown lengthening procedure to adjust gingival levels before being included in this study. Patients in the intervention group I will take zinc gluconate 50 mg 1 per day to increase zinc level with phytase supplement 176mg (800FTU) 2 tablets per day to give the maximum absorption of zinc, both supplements will be given for 4 days before botulinum toxin injections. Patients in the intervention group II will take zinc gluconate 50 mg 1 per day to increase zinc level, 4 days before botulinum toxin injections. Patients in the control group will receive the Botulinum toxin injections only Clinical photographs will be taken at baseline, 2 weeks, 1 month, 3 months postoperatively.
Key facts
- Study ID
- NCT06577285
- Run by
- Cairo University
- People needed
- 36
- Starts
- 2024-06-01
- Expected to finish
- 2025-06-01
- Last updated by the study team
- 2024-09-23
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients with excessive gingival display >3mm and with normal clinical crown dimensions.
- Adults >18 years.
- Non-smokers.
- Systemically healthy.
- Hypermobile lip and mild VME.
You may not qualify if…
- Severe VME.
- Pregnant or lactating females.
- Patients with inflamed gingiva or gingival enlargement.
- Inflammation or infection at the site of injection.
- Patients with known allergy to any of the components of BTX-A or BTX-B (i.e. BTX, human albumin, saline, lactose and sodium succinate).
- Patients using anticholinesterase or other agents interfering with neuromuscular transmission.
- Psychologically unstable or who have questionable motives and unrealistic expectations.
- Dependent on intact facial movements and expressions for their livelihood (e.g. actors, singers, musicians and other media personalities).
- Afflicted with a neuromuscular disorder (e.g. myasthenia gravis, Eaton- Lambert syndrome).
Where it is running
- Faculty of Dentistry Cairo University — Cairo, Egypt (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.